Merck, Inc.
🇵🇭Philippines
Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)
Phase 2
Completed
- Conditions
- OverweightObesityBody Weight
- Interventions
- Drug: SCH 497079Drug: Placebo
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 401
- Registration Number
- NCT00642993
An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)
Phase 1
Completed
- Conditions
- Diabetes Mellitus Non-insulin-dependent
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2015-02-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT00642798
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
Phase 2
Terminated
- Conditions
- Brain NeoplasmBreast NeoplasmSecond Neoplasm
- Interventions
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT00638963
A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00635778
A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 63
- Registration Number
- NCT00635648
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
Phase 1
Completed
- Conditions
- HPV Infections
- Interventions
- Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00635830
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)
Phase 1
Completed
- Conditions
- Hepatitis C
- Interventions
- Drug: MK-3281Drug: Placebo to MK-3281
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00635804
A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)
Phase 1
Completed
- Conditions
- Advanced Cancer RelapsedAdvanced Cancer Refractory
- Interventions
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 25
- Registration Number
- NCT00632931
Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT00632073
A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)
Phase 3
Completed
- Conditions
- Sleep Initiation and Maintenance DisordersMental DisordersDyssomniasSleep Disorder, IntrinsicSleep Disorders
- Interventions
- Drug: EsmirtazapineDrug: Placebo
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 460
- Registration Number
- NCT00631657
© Copyright 2025. All Rights Reserved by MedPath